No profile data available.
MetaVia Inc. (MTVA) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Cambridge, United States, with about 8 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$27.59 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $9.29 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
MetaVia reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$9.29 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Aligos Therapeutics, Inc. (ALGS), Hepion Pharmaceuticals, Inc. (HEPA), Chemomab Therapeutics Ltd. (CMMB), Exicure, Inc. (XCUR).